Analysis of targeted somatic mutations in pleomorphic carcinoma of the lung using next-generation sequencing technique.
Comutation
TP53 mutation
next-generation sequencing
pleomorphic carcinoma
Journal
Thoracic cancer
ISSN: 1759-7714
Titre abrégé: Thorac Cancer
Pays: Singapore
ID NLM: 101531441
Informations de publication
Date de publication:
08 2020
08 2020
Historique:
received:
30
04
2020
revised:
25
05
2020
accepted:
26
05
2020
pubmed:
25
6
2020
medline:
13
8
2021
entrez:
25
6
2020
Statut:
ppublish
Résumé
Pleomorphic carcinoma (PC) of the lung is a rare type of lung cancer with aggressive characteristics and a poor prognosis. Because it is rare, the molecular characteristics of PC remain unclear. A gene mutation analysis was performed using next-generation sequencing (NGS) in patients with PC of the lung who had undergone surgical resection. A total of nine patients were enrolled in the study. All the patients were male and eight had a history of smoking. Eight tumors contained spindle cells and three contained giant cells. Mutations considered significant were found in eight of the nine patients: in TP53 in five patients, in MET in two patients, and in ALK, ERBB2, PIK3CA, APC, NF1, and CDKN2A in one patient each. No EGFR mutation was detected in our analysis. Co-mutations were detected in three patients: TP53 with MET and NF1, TP53 with ERBB2, and PIK3CA with CDKN2A. TP53 mutations were detected most frequently in PC of the lung with NGS analysis. Different co-mutations were seen in several specimens. Significant findings of the study This study demonstrates that mutations in the TP53 gene are frequently found and co-mutations are sometimes found in pleomorphic carcinoma of the lung using genomic profiling analysis. What this study adds Our results will help to analogize the genetic characteristics and potential target of molecular-targeted agents of pleomorphic carcinoma of the lung.
Sections du résumé
BACKGROUND
Pleomorphic carcinoma (PC) of the lung is a rare type of lung cancer with aggressive characteristics and a poor prognosis. Because it is rare, the molecular characteristics of PC remain unclear.
METHODS
A gene mutation analysis was performed using next-generation sequencing (NGS) in patients with PC of the lung who had undergone surgical resection.
RESULTS
A total of nine patients were enrolled in the study. All the patients were male and eight had a history of smoking. Eight tumors contained spindle cells and three contained giant cells. Mutations considered significant were found in eight of the nine patients: in TP53 in five patients, in MET in two patients, and in ALK, ERBB2, PIK3CA, APC, NF1, and CDKN2A in one patient each. No EGFR mutation was detected in our analysis. Co-mutations were detected in three patients: TP53 with MET and NF1, TP53 with ERBB2, and PIK3CA with CDKN2A.
CONCLUSIONS
TP53 mutations were detected most frequently in PC of the lung with NGS analysis. Different co-mutations were seen in several specimens.
KEY POINTS
Significant findings of the study This study demonstrates that mutations in the TP53 gene are frequently found and co-mutations are sometimes found in pleomorphic carcinoma of the lung using genomic profiling analysis. What this study adds Our results will help to analogize the genetic characteristics and potential target of molecular-targeted agents of pleomorphic carcinoma of the lung.
Identifiants
pubmed: 32578376
doi: 10.1111/1759-7714.13536
pmc: PMC7396383
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
2262-2269Subventions
Organisme : Health Foundation
Pays : International
Informations de copyright
© 2020 The Authors. Thoracic Cancer published by China Lung Oncology Group and John Wiley & Sons Australia, Ltd.
Références
N Engl J Med. 2009 Sep 3;361(10):947-57
pubmed: 19692680
Cancer Discov. 2017 Aug;7(8):818-831
pubmed: 28572459
Cancer Causes Control. 2011 Dec;22(12):1669-80
pubmed: 21960145
Am J Clin Oncol. 2016 Jun;39(3):215-22
pubmed: 25068469
J Clin Oncol. 2016 Mar 1;34(7):721-30
pubmed: 26729443
Lung Cancer. 2010 May;68(2):204-10
pubmed: 19577320
Lancet Oncol. 2016 Jul;17(7):984-993
pubmed: 27283860
Nature. 2012 Sep 27;489(7417):519-25
pubmed: 22960745
Sci Rep. 2017 Jun 21;7(1):3947
pubmed: 28638113
Int J Cancer. 2009 Nov 15;125(10):2479-82
pubmed: 19681124
Respir Med Case Rep. 2019 Jun 11;28:100879
pubmed: 31249776
Cell. 2012 Sep 14;150(6):1121-34
pubmed: 22980976
Science. 2015 Apr 3;348(6230):124-8
pubmed: 25765070
J Clin Oncol. 2016 Mar 10;34(8):794-802
pubmed: 26215952
N Engl J Med. 2014 Nov 20;371(21):1963-71
pubmed: 25264305
Science. 2014 Oct 10;346(6206):256-9
pubmed: 25301631
J Clin Oncol. 2012 Mar 10;30(8):863-70
pubmed: 22215748
N Engl J Med. 2014 Mar 27;370(13):1189-97
pubmed: 24670165
J Thorac Oncol. 2013 Aug;8(8):e75-8
pubmed: 23857406
Oncologist. 2015 Mar;20(3):316-22
pubmed: 25721120
J Thorac Oncol. 2014 Feb;9(2):154-62
pubmed: 24419411
J Thorac Oncol. 2010 Apr;5(4):460-5
pubmed: 20107421
PLoS One. 2015 Mar 26;10(3):e0122066
pubmed: 25811670
Nature. 2014 Jul 31;511(7511):543-50
pubmed: 25079552
Lung Cancer. 2018 Aug;122:113-119
pubmed: 30032818
PLoS One. 2013 Aug 01;8(8):e69794
pubmed: 23936355
Mod Pathol. 2016 Aug;29(8):824-31
pubmed: 27174587
Lung Cancer. 2017 Apr;106:131-137
pubmed: 28285687
Am J Surg Pathol. 2008 Nov;32(11):1727-35
pubmed: 18769330
N Engl J Med. 2010 Jun 24;362(25):2380-8
pubmed: 20573926
Lancet Oncol. 2011 Feb;12(2):175-80
pubmed: 21277552
Ann Surg Oncol. 2011 Oct;18(10):2952-60
pubmed: 21409490
Jpn J Clin Oncol. 2010 Feb;40(2):101-6
pubmed: 20031962
Lung Cancer. 2012 Sep;77(3):507-14
pubmed: 22705117
J Clin Oncol. 2009 Sep 10;27(26):4247-53
pubmed: 19667264
Jpn J Clin Oncol. 2006 May;36(5):309-24
pubmed: 16735374
J Thorac Oncol. 2016 Aug;11(8):1282-1292
pubmed: 27156442
Oncologist. 2019 Nov;24(11):e1070-e1081
pubmed: 30902917
J Thorac Oncol. 2020 May;15(5):766-776
pubmed: 31988001
Ann Oncol. 2015 Aug;26(8):1748-53
pubmed: 25969368
J Thorac Oncol. 2015 May;10(5):e28-e29
pubmed: 25898961
J Cancer Res Clin Oncol. 2011 Aug;137(8):1203-11
pubmed: 21626008
BMC Res Notes. 2015 Dec 18;8:800
pubmed: 26682906
Cancer Res. 2000 Dec 15;60(24):6788-93
pubmed: 11156366
Lung Cancer. 2007 Oct;58(1):112-5
pubmed: 17574296
Onco Targets Ther. 2013 Dec 19;7:57-68
pubmed: 24379683
J Exp Ther Oncol. 2016 Jul;11(3):189-194
pubmed: 28471124
Genet Mol Biol. 2013 Sep;36(3):455-64
pubmed: 24130455
Lung Cancer. 2017 Sep;111:23-29
pubmed: 28838393
Expert Opin Ther Targets. 2011 Mar;15(3):351-3
pubmed: 21208134
J Thorac Cardiovasc Surg. 2007 Aug;134(2):399-404
pubmed: 17662779
N Engl J Med. 2013 Jun 20;368(25):2385-94
pubmed: 23724913
Cell. 2012 Sep 14;150(6):1107-20
pubmed: 22980975
Science. 1991 Jul 5;253(5015):49-53
pubmed: 1905840
Clin Cancer Res. 2009 May 1;15(9):3143-9
pubmed: 19383809
Hum Pathol. 2016 Mar;49:99-106
pubmed: 26826416
Transl Oncol. 2017 Apr;10(2):115-120
pubmed: 28081478
Lung Cancer. 2014 Aug;85(2):276-81
pubmed: 24997135
Carcinogenesis. 2014 Jun;35(6):1196-208
pubmed: 24658181
Br J Cancer. 1993 Oct;68(4):653-61
pubmed: 8398688
Anticancer Res. 2015 Jan;35(1):389-94
pubmed: 25550577
Thorac Cancer. 2019 Dec;10(12):2312-2315
pubmed: 31617320
Med Oncol. 2009;26(3):287-91
pubmed: 18989796
CA Cancer J Clin. 2013 Jan;63(1):11-30
pubmed: 23335087